11,199 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Purchased by Kestra Private Wealth Services LLC

Kestra Private Wealth Services LLC bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 11,199 shares of the biopharmaceutical company’s stock, valued at approximately $414,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Artisan Partners Limited Partnership lifted its holdings in shares of Halozyme Therapeutics by 3.4% during the third quarter. Artisan Partners Limited Partnership now owns 7,712,874 shares of the biopharmaceutical company’s stock worth $294,632,000 after purchasing an additional 253,363 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Halozyme Therapeutics by 0.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,698,359 shares of the biopharmaceutical company’s stock valued at $64,877,000 after acquiring an additional 15,902 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Halozyme Therapeutics by 174.5% in the third quarter. Allspring Global Investments Holdings LLC now owns 887,274 shares of the biopharmaceutical company’s stock valued at $33,894,000 after acquiring an additional 563,989 shares during the period. Kennedy Capital Management LLC lifted its holdings in Halozyme Therapeutics by 4.7% in the third quarter. Kennedy Capital Management LLC now owns 646,475 shares of the biopharmaceutical company’s stock valued at $24,695,000 after acquiring an additional 28,880 shares during the period. Finally, Principal Financial Group Inc. lifted its holdings in Halozyme Therapeutics by 10.9% in the third quarter. Principal Financial Group Inc. now owns 590,651 shares of the biopharmaceutical company’s stock valued at $22,563,000 after acquiring an additional 58,123 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Activity

In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $39.55, for a total value of $395,500.00. Following the transaction, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,191,868.90. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 30,000 shares of company stock valued at $1,196,800 in the last quarter. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $40.86 on Tuesday. Halozyme Therapeutics, Inc. has a fifty-two week low of $29.85 and a fifty-two week high of $45.00. The stock’s fifty day moving average is $40.01 and its two-hundred day moving average is $37.94. The firm has a market capitalization of $5.19 billion, a P/E ratio of 19.37, a price-to-earnings-growth ratio of 0.47 and a beta of 1.26. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The business had revenue of $230.04 million during the quarter, compared to analyst estimates of $235.25 million. On average, research analysts anticipate that Halozyme Therapeutics, Inc. will post 3.43 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on HALO shares. TheStreet downgraded Halozyme Therapeutics from a “b-” rating to a “c+” rating in a report on Monday, January 22nd. TD Cowen began coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They issued an “outperform” rating and a $54.00 price target for the company. The Goldman Sachs Group cut their price objective on Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating for the company in a research report on Thursday, January 18th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday, April 30th. Finally, JMP Securities reiterated a “market outperform” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $53.29.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.